Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma? | Zendy

Asude Aksoy | Zendy; Emin Tamer Elkıran | Zendy; Hakan Harputluoğlu | Zendy; Adile Ferda Dağlı | Zendy; Abdurrahman Işıkdoğan | Zendy; Zuhat Urakçı | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?

Author(s) -

Asude Aksoy,

Emin Tamer Elkıran,

Hakan Harputluoğlu,

Adile Ferda Dağlı,

Abdurrahman Işıkdoğan,

Zuhat Urakçı

Publication year - 2017

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.206865

Subject(s) - ercc1 , immunohistochemistry , medicine , nasopharyngeal carcinoma , stage (stratigraphy) , oncology , p53 expression , biopsy , biomarker , chemotherapy , carcinoma , pathology , gene , radiation therapy , biology , nucleotide excision repair , dna repair , paleontology , biochemistry

To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research